Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
Date:10/28/2008

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated dosing ANA598 in patients chronically infected with hepatitis C virus (HCV) in a Phase Ib study. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor. The Phase Ib clinical trial is a double-blind, placebo-controlled study that will evaluate the tolerability, pharmacokinetics and viral kinetics of multiple, ascending doses of ANA598 over a period of three days. Anadys expects to enroll approximately 30 patients in the study of ANA598 at doses of 200 mg bid (twice-a-day), 400 mg bid and 800 mg bid.

"ANA598 demonstrated favorable tolerability and pharmacokinetics as a single dose in healthy volunteers in our recently concluded Phase I study," said James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We look forward to building upon these results and testing the compound in HCV patients, first in this monotherapy study and subsequently in combination studies. We expect the maximal benefit of direct antivirals to be realized when used in combination regimens incorporating multiple anti-HCV agents."

ANA598 Phase Ib Study

In the Phase Ib monotherapy study, ANA598 will be administered to naive genotype 1a and 1b patients over three days, at doses of 200 mg bid, 400 mg bid or 800 mg bid. Ten patients are planned to be enrolled in each of the three cohorts - eight on active treatment and two on placebo. Anadys expects to have viral load data from all three cohorts in the first quarter of 2009. Anadys may elect to explore other dose levels of ANA598 and/or once-daily dosing based on data from the first three cohorts.

About ANA598

<
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Anadys Pharmaceuticals to Present at Bio Investor Forum
2. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
5. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
6. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
11. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... “In 2013, a vehicle crash occurred every 5 ... a recently released article on 2013 Washington auto accident ... auto accident every 12 minutes, and a motorcyclist is involved ... the 2013 statistics, between now and this same time tomorrow, ... of an auto accident is real and impending - five ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... and Jupiter, FL. , Barton Associates decided ... demand for healthcare providers. The United States is in ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary recommendations ... acute coronary syndromes (ACS) are published today in ... was written jointly by the European Heart Rhythm ... and the European Association of Percutaneous Cardiovascular Interventions ... Bulent Gorenek (Turkey), chairperson of the task force, ...
(Date:8/30/2014)... The therapeutic benefit of revascularisation in coronary artery ... revascularisation guidelines presented at ESC Congress by joint ... the European Society of Cardiology (ESC) and Professor ... Cardio-Thoracic Surgery (EACTS). The joint guidelines are published ... (1), on the ESC Website (2), in EuroIntervention ...
(Date:8/29/2014)... 30, 2014 AGH Healthy Happenings, a ... Doctors in Delaware at Atlantic General Hospital, are ... services. In addition to no-cost blood pressure screenings at ... aid care at local sports tournaments. , In ... staff provide free disease management and falls prevention workshops ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... Strictly embargoed until: 00.01 GMT, Friday, 12 October, ... world,s,maternal mortality ratio (the number of maternal deaths per ... Development Goal (MDG),5, which aims to improve maternal health ... While an annual decline of 5.5 per cent in ...
... Calif., Oct. 11 Each year, more than,90,000 ... of gynecological cancer.,Although the overall death rate for ... cancer has increased slightly. Dr. Stan Wasbin, ... provides an overview of gynecological,cancer, stressing the importance ...
... little,cooler for the patients at Children,s National Medical Center, ... will make their annual,visit. The team will also launch ... Caps., Courage Caps are team-issued and branded hats ... games and online at NHL.com, with,100 percent of the ...
... Cancer researchers have long worked to understand why some ... to stop the production of testosterone and other androgens ... detected that androgen-synthesizing proteins are present within cancer cells, ... to produce their own androgens. , The presence ...
... School of Medicine have found that professional welders who ... at risk for loss of sense of smell. ... the first study to clearly demonstrate that welders who ... at risk for damaging their sense of smell, says ...
... 11 Six earthbound "angels" who have,brightened the lives ... Shield of Michigan. The Caring for Children Angel ... children,s lives. The awards have been,sponsored annually by the ... be honored at a Friday, Nov. 9 reception and ...
Cached Medicine News:Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 2Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 3Health News:The Silent Killer, Ovarian Cancer on Your Cancer Today (TM) 2Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Penn study suggests professional welders at risk for loss of sense of smell 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
Titanium. 0.12 mm 1 x 2 teeth with 6 mm platform and 2.0 mm angled tips. Flat serrated handle, dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Narrow 4 mm long smooth platform. Serrated handle with polished finish....
Medicine Products: